This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (Presently Amended)   A method for ~~detecting~~ <u>determining the</u> binding of a test substance to an α2δ subunit of a calcium channel comprising the steps of :

    (a)   contacting a <u>sample of</u> neuroblastoma cell ~~membrane~~ <u>membranes</u> ~~sample~~ comprising the α2δ subunit of a calcium channel with gabapentin and a test substance;

    (b)   detecting binding of the gabapentin to the cell ~~membrane~~ <u>membranes;</u> and

    (c)   comparing the ~~level~~ amount of binding of gabapentin <u>of the sample</u> as compared with a control sample lacking the test substance, <u>thereby determining the binding of the test substance to the α2δ subunit.</u>

2. (Original)   The method of claim 1 wherein the cell membranes are part of intact cells.

3. (Original)   The method of claim 1 wherein the cell membranes are obtained from an isolated cell membrane preparation.

4. (Original)   The method of claim 1 wherein the neuroblastoma cell membranes are IMR32, SK-N-MC or NG 108 cell membranes.

5. (Original)   The method of claim 1 wherein the neuroblastoma cell membranes are differentiated neuroblastoma cell membranes.

6. (Original)   The method of claim 5 wherein the differentiated cell membranes are obtained following incubation with BrdU.

7. (Original) The method of claim 1 further comprising the step of separating the cell

membranes from unbound gabapentin.

8. (Original) The method of claim 1 wherein the comparing step comprises measuring

binding of labeled gabapentin bound to the cell membranes.

9. (Original) A compound identified using the method of claim 1.

10. (Original) A test substance identified by a method comprising the steps of:

(a) contacting a neuroblastoma cell membrane sample comprising $\alpha2\delta$ subunit

of a calcium channel with gabapentin and a test substance;

(b) detecting binding of the gabapentin to the cell membrane; and

(c) comparing the level of binding of gabapentin as compared with a control

sample lacking the test substance.

11. (Canceled).